tiprankstipranks
Trending News
More News >
Circassia Pharmaceuticals PLC (GB:NIOX)
LSE:NIOX

Circassia Pharmaceuticals (NIOX) Stock Statistics & Valuation Metrics

Compare
13 Followers

Total Valuation

Circassia Pharmaceuticals has a market cap or net worth of £286.35M. The enterprise value is 15.28B.
Market Cap£286.35M
Enterprise Value15.28B

Share Statistics

Circassia Pharmaceuticals has 417,417,570 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding417,417,570
Owned by Insiders0.89%
Owned by Institutions<0.01%

Financial Efficiency

Circassia Pharmaceuticals’s return on equity (ROE) is 0.06 and return on invested capital (ROIC) is 5.50%.
Return on Equity (ROE)0.06
Return on Assets (ROA)0.05
Return on Invested Capital (ROIC)5.50%
Return on Capital Employed (ROCE)0.13
Revenue Per Employee459.34K
Profits Per Employee89.01K
Employee Count91
Asset Turnover0.61
Inventory Turnover2.90

Valuation Ratios

The current PE Ratio of Circassia Pharmaceuticals is 7.12K. Circassia Pharmaceuticals’s PEG ratio is 2.78.
PE Ratio7.12K
PS Ratio0.00
PB Ratio186.82
Price to Fair Value442.81
Price to FCF2.32K
Price to Operating Cash Flow2.28K
PEG Ratio2.78

Income Statement

In the last 12 months, Circassia Pharmaceuticals had revenue of 41.80M and earned 3.70M in profits. Earnings per share was 0.01.
Revenue41.80M
Gross Profit30.20M
Operating Income7.70M
Pretax Income7.80M
Net Income3.70M
EBITDA12.20M
Earnings Per Share (EPS)0.01

Cash Flow

In the last 12 months, operating cash flow was 17.60M and capital expenditures 0.00, giving a free cash flow of 17.60M billion.
Operating Cash Flow17.60M
Free Cash Flow17.60M
Free Cash Flow per Share0.04

Dividends & Yields

Circassia Pharmaceuticals pays an annual dividend of 1.25p, resulting in a dividend yield of 182.22%
Dividend Per Share1.25p
Dividend Yield182.22%
Payout RatioN/A
Free Cash Flow Yield
Earnings Yield

Stock Price Statistics

Beta1.22
52-Week Price Change2.42%
50-Day Moving Average65.91
200-Day Moving Average63.62
Relative Strength Index (RSI)54.52
Average Volume (3m)1.76M

Important Dates

Circassia Pharmaceuticals upcoming earnings date is Sep 11, 2025, TBA Not Confirmed.
Last Earnings DateApr 1, 2025
Next Earnings DateSep 11, 2025
Ex-Dividend DateMay 15, 2025

Financial Position

Circassia Pharmaceuticals as a current ratio of 2.60, with Debt / Equity ratio of 1.22%
Current Ratio2.60
Quick Ratio2.11
Debt to Market Cap0.00
Net Debt to EBITDA-0.77
Interest Coverage Ratio38.50

Taxes

In the past 12 months, Circassia Pharmaceuticals has paid 4.40M in taxes.
Income Tax4.40M
Effective Tax Rate0.56

Enterprise Valuation

Circassia Pharmaceuticals EV to EBITDA ratio is 2.16K, with an EV/FCF ratio of 1.63K.
EV to Sales630.09
EV to EBITDA2.16K
EV to Free Cash Flow1.63K
EV to Operating Cash Flow1.53K

Balance Sheet

Circassia Pharmaceuticals has £10.90M in cash and marketable securities with £1.50M in debt, giving a net cash position of -£9.40M billion.
Cash & Marketable Securities£10.90M
Total Debt£1.50M
Net Cash-£9.40M
Net Cash Per Share-£0.02
Tangible Book Value Per Share£0.08

Margins

Gross margin is 70.93%, with operating margin of 18.42%, and net profit margin of 8.85%.
Gross Margin70.93%
Operating Margin18.42%
Pretax Margin18.66%
Net Profit Margin8.85%
EBITDA Margin29.19%
EBIT Margin18.90%

Analyst Forecast

The average price target for Circassia Pharmaceuticals is £85.67, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target£85.67
Price Target Upside24.88% Upside
Analyst ConsensusStrong Buy
Analyst Count3
Revenue Growth Forecast13.59%
EPS Growth Forecast-66.27%

Scores

Smart Score7
AI Score69
What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis